Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 700

1.

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.

Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, Piper AE, Leung Y, Albariño CG, Crozier I, Ellebedy AH, Sidney J, Sette A, Yu T, Nielsen SCA, Goff AJ, Spiropoulou CF, Saphire EO, Cavet G, Kawaoka Y, Mehta AK, Glass PJ, Boyd SD, Ahmed R.

Cell. 2019 May 30;177(6):1566-1582.e17. doi: 10.1016/j.cell.2019.04.036. Epub 2019 May 16.

PMID:
31104840
2.

A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses.

Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y.

Nat Microbiol. 2019 Apr 29. doi: 10.1038/s41564-019-0433-6. [Epub ahead of print]

PMID:
31036910
3.

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018.

Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y.

Viruses. 2019 Apr 2;11(4). pii: E321. doi: 10.3390/v11040321.

4.

Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity.

Oishi K, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2019 Mar 6;10:432. doi: 10.3389/fmicb.2019.00432. eCollection 2019.

5.

Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.

Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y.

Nat Microbiol. 2019 Jun;4(6):1024-1034. doi: 10.1038/s41564-019-0401-1. Epub 2019 Mar 18.

PMID:
30886361
6.

Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw.

Kojima Y, Kawaoka Y, Sawada S, Hayashida S, Okuyama K, Yutori H, Kawakita A, Ishida S, Soutome S, Yanamoto S, Umeda M, Iwai H.

J Bone Miner Metab. 2019 Mar 4. doi: 10.1007/s00774-019-00994-1. [Epub ahead of print]

PMID:
30830278
7.

Plasma lipidome reveals critical illness and recovery from human Ebola virus disease.

Kyle JE, Burnum-Johnson KE, Wendler JP, Eisfeld AJ, Halfmann PJ, Watanabe T, Sahr F, Smith RD, Kawaoka Y, Waters KM, Metz TO.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3919-3928. doi: 10.1073/pnas.1815356116. Epub 2019 Feb 11.

PMID:
30808769
8.

Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons.

Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y.

Euro Surveill. 2019 Feb;24(6). doi: 10.2807/1560-7917.ES.2019.24.6.1800467.

9.

Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.

Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y.

Viruses. 2019 Feb 11;11(2). pii: E149. doi: 10.3390/v11020149.

10.

Host protein mimics viral protein to hinder infection by Ebola virus.

Yamayoshi S, Kawaoka Y.

Nature. 2019 Feb;566(7743):190-191. doi: 10.1038/d41586-019-00182-1. No abstract available.

PMID:
30737499
11.

Injectable Excipients as Novel Influenza Vaccine Adjuvants.

Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y.

Front Microbiol. 2019 Jan 24;10:19. doi: 10.3389/fmicb.2019.00019. eCollection 2019.

12.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

PMID:
30728263
13.

Predicting the Next Influenza Pandemics.

Neumann G, Kawaoka Y.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S14-S20. doi: 10.1093/infdis/jiz040.

PMID:
30715371
14.

C57BL/6J and C57BL/6NJ Mice Are Differentially Susceptible to Inflammation-Associated Disease Caused by Influenza A Virus.

Eisfeld AJ, Gasper DJ, Suresh M, Kawaoka Y.

Front Microbiol. 2019 Jan 17;9:3307. doi: 10.3389/fmicb.2018.03307. eCollection 2018.

15.

Antibody-free digital influenza virus counting based on neuraminidase activity.

Tabata KV, Minagawa Y, Kawaguchi Y, Ono M, Moriizumi Y, Yamayoshi S, Fujioka Y, Ohba Y, Kawaoka Y, Noji H.

Sci Rep. 2019 Jan 31;9(1):1067. doi: 10.1038/s41598-018-37994-6.

16.

Current and future influenza vaccines.

Yamayoshi S, Kawaoka Y.

Nat Med. 2019 Feb;25(2):212-220. doi: 10.1038/s41591-018-0340-z. Epub 2019 Jan 28. Review.

PMID:
30692696
17.

Molecular Mechanism of Externalization of Phosphatidylserine on the Surface of Ebola Virus Particles.

Nanbo A, Kawaoka Y.

DNA Cell Biol. 2019 Feb;38(2):115-120. doi: 10.1089/dna.2018.4485. Epub 2019 Jan 7. Review.

PMID:
30615471
18.

Network-Guided Discovery of Influenza Virus Replication Host Factors.

Ackerman EE, Kawakami E, Katoh M, Watanabe T, Watanabe S, Tomita Y, Lopes TJ, Matsuoka Y, Kitano H, Shoemaker JE, Kawaoka Y.

MBio. 2018 Dec 18;9(6). pii: e02002-18. doi: 10.1128/mBio.02002-18.

19.

Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses.

Gu C, Zeng X, Song Y, Li Y, Liu L, Kawaoka Y, Zhao D, Chen H.

Sci China Life Sci. 2019 Jan;62(1):76-83. doi: 10.1007/s11427-018-9439-0. Epub 2018 Nov 30.

PMID:
30515728
20.

Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses.

Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y.

Front Microbiol. 2018 Nov 1;9:2660. doi: 10.3389/fmicb.2018.02660. eCollection 2018.

21.

Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, Ueda N, Iwata E, Nakahara H, Kobayashi M, Soutome S, Yamada SI, Tojyo I, Kojima Y, Umeda M, Fujita S, Kurita H, Shibuya Y, Kirita T, Komori T; Japanese Study Group of Co-operative Dentistry with Medicine (JCDM).

Osteoporos Int. 2019 Jan;30(1):231-239. doi: 10.1007/s00198-018-4746-8. Epub 2018 Nov 7.

PMID:
30406309
22.

A Defect in Influenza A Virus Particle Assembly Specific to Primary Human Macrophages.

Bedi S, Noda T, Kawaoka Y, Ono A.

MBio. 2018 Oct 23;9(5). pii: e01916-18. doi: 10.1128/mBio.01916-18.

23.

Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex at 3.6 Å resolution.

Sugita Y, Matsunami H, Kawaoka Y, Noda T, Wolf M.

Nature. 2018 Nov;563(7729):137-140. doi: 10.1038/s41586-018-0630-0. Epub 2018 Oct 17.

PMID:
30333622
24.

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene.

Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA.

Cell Host Microbe. 2018 Oct 10;24(4):569-578.e4. doi: 10.1016/j.chom.2018.09.010.

PMID:
30308159
25.

Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus.

Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y.

J Clin Virol. 2018 Nov;108:105-111. doi: 10.1016/j.jcv.2018.09.016. Epub 2018 Sep 26.

PMID:
30292135
26.

The Cellular DExD/H-Box RNA Helicase UAP56 Co-localizes With the Influenza A Virus NS1 Protein.

Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y.

Front Microbiol. 2018 Sep 12;9:2192. doi: 10.3389/fmicb.2018.02192. eCollection 2018.

27.

Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A(H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus.

Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y.

Emerg Infect Dis. 2018 Oct;24(10):1910-1913. doi: 10.3201/eid2410.180403.

28.

Selection of Antigenically Advanced Variants of Influenza Viruses.

Neumann G, Fan S, Kawaoka Y.

Methods Mol Biol. 2018;1836:461-486. doi: 10.1007/978-1-4939-8678-1_22.

PMID:
30151587
29.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

30.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

PMID:
30092199
31.

Host Factor Nucleoporin 93 Is Involved in the Nuclear Export of Influenza Virus RNA.

Furusawa Y, Yamada S, Kawaoka Y.

Front Microbiol. 2018 Jul 24;9:1675. doi: 10.3389/fmicb.2018.01675. eCollection 2018.

32.

The Induction of IL-1β Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection.

Halfmann P, Hill-Batorski L, Kawaoka Y.

J Infect Dis. 2018 Nov 22;218(suppl_5):S504-S507. doi: 10.1093/infdis/jiy433.

PMID:
30060221
33.

N-Terminal Acetylation by NatB Is Required for the Shutoff Activity of Influenza A Virus PA-X.

Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y.

Cell Rep. 2018 Jul 24;24(4):851-860. doi: 10.1016/j.celrep.2018.06.078.

34.

Strain-Specific Contribution of Eukaryotic Elongation Factor 1 Gamma to the Translation of Influenza A Virus Proteins.

Sammaibashi S, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2018 Jun 29;9:1446. doi: 10.3389/fmicb.2018.01446. eCollection 2018.

35.

Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.

Hatta Y, Boltz D, Sarawar S, Kawaoka Y, Neumann G, Bilsel P.

Vaccine. 2018 Aug 9;36(33):5097-5103. doi: 10.1016/j.vaccine.2018.06.053. Epub 2018 Jul 13.

36.

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype.

Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y.

Front Microbiol. 2018 Jun 25;9:1346. doi: 10.3389/fmicb.2018.01346. eCollection 2018.

37.

In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs.

Ueki H, Wang IH, Fukuyama S, Katsura H, da Silva Lopes TJ, Neumann G, Kawaoka Y.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6622-E6629. doi: 10.1073/pnas.1806265115. Epub 2018 Jun 25.

38.

Diversity of Influenza A(H5N1) Viruses in Infected Humans, Northern Vietnam, 2004-2010.

Imai H, Dinis JM, Zhong G, Moncla LH, Lopes TJS, McBride R, Thompson AJ, Peng W, Le MTQ, Hanson A, Lauck M, Sakai-Tagawa Y, Yamada S, Eggenberger J, O'Connor DH, Suzuki Y, Hatta M, Paulson JC, Neumann G, Friedrich TC, Kawaoka Y.

Emerg Infect Dis. 2018 Jul;24(7):1128-1238. doi: 10.3201/eid2407.171441.

39.

The Marmoset as an Animal Model of Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the Conventional or Tracheal Spray Route.

Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y.

Front Microbiol. 2018 May 9;9:844. doi: 10.3389/fmicb.2018.00844. eCollection 2018.

40.

Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin.

Kuwahara T, Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Takahashi H, Suzuki N, Kawaoka Y, Watanabe S, Odagiri T.

Jpn J Infect Dis. 2018 May 24;71(3):234-238. doi: 10.7883/yoken.JJID.2017.551. Epub 2018 Apr 27.

41.

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus.

Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y.

J Vet Med Sci. 2018 Jun 29;80(6):1020-1024. doi: 10.1292/jvms.18-0146. Epub 2018 Apr 17.

42.

A Critical Domain of Ebolavirus Envelope Glycoprotein Determines Glycoform and Infectivity.

Fujihira H, Usami K, Matsuno K, Takeuchi H, Denda-Nagai K, Furukawa JI, Shinohara Y, Takada A, Kawaoka Y, Irimura T.

Sci Rep. 2018 Apr 3;8(1):5495. doi: 10.1038/s41598-018-23357-8.

43.

Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route.

Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Jose da Silva Lopes T, Ito M, Fukuyama S, Hasegawa H, Kawaoka Y.

Sci Rep. 2018 Mar 19;8(1):4801. doi: 10.1038/s41598-018-23022-0.

44.

Influenza A virus nucleoprotein is acetylated by histone acetyltransferases PCAF and GCN5.

Hatakeyama D, Shoji M, Yamayoshi S, Yoh R, Ohmi N, Takenaka S, Saitoh A, Arakaki Y, Masuda A, Komatsu T, Nagano R, Nakano M, Noda T, Kawaoka Y, Kuzuhara T.

J Biol Chem. 2018 May 11;293(19):7126-7138. doi: 10.1074/jbc.RA117.001683. Epub 2018 Mar 19.

45.

Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans.

Yamayoshi S, Kiso M, Yasuhara A, Ito M, Shu Y, Kawaoka Y.

Emerg Infect Dis. 2018 Apr;24(4):746-750. doi: 10.3201/eid2404.171509.

46.

Stimulation of alpha2-adrenergic receptors impairs influenza virus infection.

Matsui K, Ozawa M, Kiso M, Yamashita M, Maekawa T, Kubota M, Sugano S, Kawaoka Y.

Sci Rep. 2018 Mar 15;8(1):4631. doi: 10.1038/s41598-018-22927-0.

47.

Lung-Derived Exosomal miR-483-3p Regulates the Innate Immune Response to Influenza Virus Infection.

Maemura T, Fukuyama S, Sugita Y, Lopes TJS, Nakao T, Noda T, Kawaoka Y.

J Infect Dis. 2018 Apr 11;217(9):1372-1382. doi: 10.1093/infdis/jiy035.

PMID:
29373693
48.

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape.

Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, Nicora CD, Purvine SO, Casey CP, Monroe ME, Weitz KK, Stratton KG, Webb-Robertson BM, Gralinski LE, Metz TO, Smith RD, Waters KM, Sims AC, Kawaoka Y, Baric RS.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E1012-E1021. doi: 10.1073/pnas.1706928115. Epub 2018 Jan 16.

49.

Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles.

Nanbo A, Maruyama J, Imai M, Ujie M, Fujioka Y, Nishide S, Takada A, Ohba Y, Kawaoka Y.

PLoS Pathog. 2018 Jan 16;14(1):e1006848. doi: 10.1371/journal.ppat.1006848. eCollection 2018 Jan.

50.

Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast.

Oishi K, Yamayoshi S, Kawaoka Y.

Virology. 2018 Mar;516:71-75. doi: 10.1016/j.virol.2018.01.004. Epub 2018 Jan 10.

Supplemental Content

Loading ...
Support Center